Eledon Pharmaceuticals, Inc. (ELDN)
| Market Cap | 208.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.05M |
| Shares Out | 59.88M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 117,392 |
| Open | 3.430 |
| Previous Close | 3.450 |
| Day's Range | 3.357 - 3.500 |
| 52-Week Range | 2.375 - 5.540 |
| Beta | -0.16 |
| Analysts | Strong Buy |
| Price Target | 12.50 (+259.2%) |
| Earnings Date | Aug 18, 2025 |
About ELDN
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney tran... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ELDN stock is "Strong Buy." The 12-month stock price target is $12.5, which is an increase of 259.20% from the latest price.
News
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will host an R&D Day in New York City on Wednesday, July 9, 2025 beginn...
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transpla...
Undercovered Dozen: Gevo, Eledon, Dorian, Iridium +
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering potential investment ideas and sparking community discussion. Aeluma, Inc. is a speculative microcap with game-changing se...
Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet
Eledon Pharmaceuticals' lead candidate, tegoprubart, shows promise in improving kidney function post-transplant, potentially becoming the new standard-of-care over tacrolimus. With a significant total...
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positi...
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D.
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
Eledon Announces Tegoprubart Use as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business
Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transpl...
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updat...
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive ini...
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart
Positive phase 1b biomarker and eGFR data achieved from phase 1b study using tegoprubart for prevention of organ rejection in kidney transplant patients. Top-line data from the phase 2 BESTOW study, u...
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its commo...
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
- First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose cont...
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C.
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation 80 participants (two-thirds of projected recruitment)...
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it has enrolled the 80th participant in its ongoing Phase 2 BESTOW trial a...
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company's management team will be hosting one-on-one meetings at the L...
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Data from 13 participants presented at the American Transplant Congress continue to support safety and tolerability profile of tegoprubart Overall mean eGFR of all reported time points after day 30 po...
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
Completed oversubscribed $50 million private placement First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rej...
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taki...
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Company reports...
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the ...
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company's ong...